Company Description
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform.
It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn.
It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home.
In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder.
It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions.
The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019.
Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
| Country | United States |
| Founded | 2011 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 61 |
| CEO | Steven Lisi |
Contact Details
Address: 900 Stewart Avenue, Suite 301 Garden City, New York 11530 United States | |
| Phone | 516 665 8200 |
| Website | beyondair.net |
Stock Details
| Ticker Symbol | XAIR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001641631 |
| CUSIP Number | 08862L202 |
| ISIN Number | US08862L2025 |
| Employer ID | 47-3812456 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Amir Avniel | Chief Executive Officer of NeuroNOS |
| Steven Adam Lisi | Chief Executive Officer and Chairman of the Board |
| Douglas Quinton Larson | Chief Financial Officer |
| Michael A. Gaul | Chief Operating Officer |
| Dr. Andrew R. Colin M.D. | Senior Medical Director Global Clinical Leadership and Member of Scientific Advisory Board |
| David R. Webster | Chief Commercial Officer |
| Dr. John Jett Ph.D. | Head of Research and Clinical Development |
| Adam Newman | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 18, 2025 | 8-K | Current Report |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 10, 2025 | 8-K | Current Report |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 20, 2025 | 10-K | Annual Report |
| Jun 18, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 5, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | PRE 14A | Other preliminary proxy statements |